Oxaliplatin

BreastfeedingPediatric
  • TRADE NAMES: Eloxatin (Sanofi-Aventis); Heloxatin
  • INDICATIONS:

    Metastatic carcinoma of the colon or rectum (in combination with fluorouracil/leucovorin (FOLFOX))

    Advanced pancreatic cancer (in combination with irinotecan/fluorouracil/leucovorin (FOLFIRINOX))

     

  • CLASS: Alkylating agent, Antineoplastic
  • HALF-LIFE: 391 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Aminoglycosides, BCG Vaccine, Capreomycin, Cardiac glycosides, Clozapine, Denosumab, Diuretics, Leflunomide, Natalizumab, Pimecrolimus, Polymyxins, Sipuleucel-T, Tacrolimus, Taxanes, Topotecan, Trastuzumab, Vaccines, Vitamin K antagonists

PREGNANCY CATEGORY: D

ANAPHYLACTIC REACTIONS

See full prescribing information for complete boxed warning.

Our database has 157 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN
HAIR
NAILS
MUCOSAL
CARDIOVASCULAR
CENTRAL NERVOUS SYSTEM
ENDOCRINE/METABOLIC
GASTROINTESTINAL/HEPATIC
GENITOURINARY
HEMATOLOGIC
LOCAL
NEUROMUSCULAR/SKELETAL
OCULAR
RENAL
RESPIRATORY
OTHER


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of oxaliplatin in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 10/31/2019

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top